Precision BioSciences Inc

Financials

Activos totales 150.16 M211.5 M238.17 M159.78 M136.39 M154.42 M Total de pasivos 105.73 M120.33 M177.74 M140.92 M80 M62.17 M Capital total 44.42 M91.17 M60.43 M18.86 M56.39 M92.25 M Total de pasivos y patrimonio neto 150.16 M211.5 M238.17 M159.78 M136.39 M154.42 M Deuda total —9.11 M27.04 M31.27 M30.05 M28.81 M Deuda neta —-134.55 M-162.54 M-85.41 M-56.27 M-86.78 M

Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.

DTIL

Financials

Precision BioSciences Inc

Noticias

Should You Buy Precision BioSciences (DTIL) After Golden Cross?

Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call - Slideshow (NASDAQ:DTIL) 2026-03-18

Jones Trading reitera calificación de acciones de Precision BioSciences por diseño de ensayo de DMD

Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call Transcript

Jefferies recorta el precio objetivo de Precision BioSciences por valoración

Jefferies reduce precio objetivo de Precision BioSciences por valuación

Jefferies cuts Precision BioSciences stock price target on valuation

Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates

Precision BioSciences recibe aprobaciones de patentes para programa de hepatitis B

Precision BioSciences recibe aprobaciones de patentes para programa de hepatitis B

Precision BioSciences receives patent allowances for hepatitis B program

Precision BioSciences presenta datos preclínicos sobre terapia para DMD